Contact
Please use this form to send email to PR contact of this press release:
IMV Inc. (Formerly Immunovaccine Inc.) Presents New Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ASCO Meeting
TO: